Author:
Leary Alexandra F,Sirohi Bhawna,Johnston Stephen RD
Publisher
Springer Science and Business Media LLC
Reference65 articles.
1. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001, 19: 3808-3816.
2. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Arteaga CL: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000, 60: 5887-5894.
3. Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H, Maehara Y: Activation of PI3K/Akt signalling and hormone resistance in breast cancer. Breast Cancer. 2006, 13: 137-144. 10.2325/jbcs.13.137.
4. Jeng MH, Yue W, Eischeid A, Wang JP, Santen RJ: Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Res Treat. 2000, 62: 167-175. 10.1023/A:1006406030612.
5. O'Regan RM, Khuri FR: Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?. Endocr Relat Cancer. 2004, 11: 191-205. 10.1677/erc.0.0110191.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献